<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364468</url>
  </required_header>
  <id_info>
    <org_study_id>KRN125/05-A04</org_study_id>
    <nct_id>NCT00364468</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients</brief_title>
  <official_title>A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <brief_summary>
    <textblock>
      To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with
      a single injection of KRN125 or multiple daily injections of filgrastim.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the duration of severe neutropenia</measure>
  </primary_outcome>
  <enrollment type="Actual">107</enrollment>
  <condition>Neutropenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed as malignant lymphoma

          -  patients who were refractory to anthracycline or anthraquinone containing chemotherapy

          -  patients who are going to receive ESHAP or CHASE treatment regimen

          -  ECOG performance status =&lt; 2

          -  patients who have appropriate bone marrow, hepatic and renal functions

          -  written informed consent

        Exclusion Criteria:

          -  double cancer

          -  history of bone marrow transplantation or PBSCT

          -  more than 2 prior chemotherapy regimens

          -  primary hematologic disease such as myelodysplastic syndrome

          -  previous radiotherapy within 4 weeks of enrollment

          -  woman of childbearing potential who were either pregnant, breast feeding

          -  patients who participated in other clinical trials within the last 4 weeks of
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomomitsu Hotta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokai region</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu region</name>
      <address>
        <city>Fukuoka, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto region</name>
      <address>
        <city>Gunma, Saitama, Tokyo, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido region</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki region</name>
      <address>
        <city>Kyoto, Mie, Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku region</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pegfilgrastim</keyword>
  <keyword>neutropenia</keyword>
  <keyword>cancer patients</keyword>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

